



# 12th International Conference on Frontotemporal Dementias and 1st International Society for Frontotemporal Dementia Congress 2020

October 7-10, 2020 • Hilton Minneapolis

## Clinical/Scientific Track

Tuesday, October 6		
Registration and Welcome Reception		
Time	Event/Title	Speaker/Participants
1800 - 1930	Registration and Welcome Reception	All conference participants

Day 1 - Wednesday, October 7 (Optional Day for Family Track Participants)		
Time	Event/Title	Speaker/Participants
0645 - 0730	<i>Breakfast</i>	All participants
Conference Overview		
0730 - 0745	Conference overview	ICFTD2020 Organizers
Session 1: Panel		
Session Moderators: Angela Lunde and Leah Forsberg, Mayo Clinic Rochester		
0745 - 0830	Panel discussion with individuals affected by FTD and their families	TBD
Session 2: Review of Clinical and Diagnostic Features of FTL D		
Session Co-Chairs: TBD		
0830 - 0845	Clinical features and diagnostic criteria of major FTL D syndromes	Bruce Miller UCSF, USA
0845 - 0900	Neuropsychological features of major FTL D syndromes	Katya Rascovsky Univ of Pennsylvania, USA
0900 - 0915	Key neuroimaging findings in major FTL D syndromes	Federica Agosta Vita-Salute San Raffaele Univ, Italy
0915 - 0930	Clinical-imaging-genetic-pathologic associations in familial FTL D	William Seeley UCSF, USA
0930 - 1000	<i>Break</i>	All participants
Session 3: Update and Controversies – Clinical and Neuropsychological Issues 1		
Session Co-Chairs: TBD		
1000 - 1015	Differentiation of behavioral variant frontotemporal dementia from Alzheimer’s dementia	David Knopman Mayo Clinic Rochester, USA
1015 - 1030	Differentiation of behavioral variant frontotemporal dementia from primary psychiatric disorders	Chiadi Onyike Johns Hopkins Univ, USA
1030 - 1045	Early detection of sporadic FTL D	Florence Pasquier Univ de Lille, France
1045 - 1100	Mixed/atypical phenotypes (FTD/PPA, amnesic, phenocopy)	Carmela Tartaglia Univ of Toronto, Canada

<b>Session 4: Update and Controversies – Clinical and Neuropsychological Issues 2</b>		
1100 - 1115	Primary progressive aphasia syndromes and primary progressive apraxia of speech	Joseph Duffy Mayo Clinic Rochester, USA
1115 - 1130	Temporal variant FTLD: left versus right	Marsel Mesulam Northwestern Univ, USA
1130 - 1145	FTD-ALS continuum and assessing FTD features in ALS	Beth Rush Mayo Clinic Florida, USA
1145 - 1200	Clinical features and diagnostic criteria of FTLD motor syndromes: Corticobasal degeneration and progressive supranuclear palsy	Irene Litvan UCSD, USA
1200-1230	Discussion	Session 3 and 4 speakers
1230 - 1330	<i>Lunch</i>	All participants
<b>Session 5: FTD Consortia</b>		
Session Co-Chairs: TBD		
1330 - 1340	ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)	Brad Boeve Mayo Clinic Rochester, USA
1340 - 1350	Genetic Frontotemporal Dementia Initiative (GENFI) and Frontotemporal Dementia Prevention Initiative (FPI)	Jonathan Rohrer Univ College London, UK
1350 - 1400	Dominantly Inherited Non-Alzheimer Dementias (DINAD)	Olivier Piguet Univ of Sydney, Australia
1400 - 1410	Neuropsychiatric International Consortium for Frontotemporal Dementia (NIC-FTD)	Yolande Pijnenberg Amsterdam UMC, Netherlands
1410 - 1420	Latin American Frontotemporal Dementia Consortium	Augustin Ibanez Favaloro Univ, Argentina
1420 -1430	Japanese Frontotemporal Dementia Consortium	Manabu Ikeda Osaka Univ, Japan
<b>Session 6: Patient Advocacy Groups</b>		
Session Co-Chairs: TBD		
1430 - 1440	Association for Frontotemporal Degeneration (AFTD)	Susan Dickinson
1440 - 1450	Bluefield Project	Rodney Pearlman
1450 - 1500	Tau Consortium	Pat Brannelly
1500 - 1510	CurePSP	Larry Golbe
1510 - 1520	CBD Solutions	Samuel Svenson
1520 - 1545	<i>Break</i>	All participants
<b>Session 7: Hot Topics – Clinical and Neuropsychological Issues</b>		
Session Co-Chairs: TBD		
1545 - 1700	Oral presentations and data blitz	Abstract authors
<b>Session 8: ISFTD Presidential Address</b>		
1700 - 1730	ISFTD Presidential Address – title TBD	Rosa Rademakers Antwerp Univ, Belgium
<b>Poster Session 1</b>		
1730 - 1900	Poster session – authors stand by posters	All participants
<b>Evening Activities</b>		
1900 - 2200	Dinner (on your own) and social activities TBD	All participants

<b>Day 2 - Thursday, October 8</b>		
<b>Time</b>	<b>Event/Title</b>	<b>Speaker/Participants</b>
0630 - 0730	<i>Breakfast</i>	All participants
<b>Session 9: Review of Neuroimaging Findings in FTLD</b>		
Session Co-Chairs: TBD		
0730 - 0745	MRI findings in bvFTD, PPA, CBS, PSP	Jennifer Whitwell Mayo Clinic Rochester, USA
0745 - 0800	FDG-PET findings in bvFTD, PPA, CBS, PSP	Val Lowe Mayo Clinic Rochester, USA
0800 - 0815	Molecular PET findings in bvFTD, PPA, CBS, PSP	Gil Rabinovici UCSF, USA
0815 - 0830	Discussion	Session 9 speakers

<b>Session 10: Review of Biofluid and Electrophysiologic Findings in FTLD</b>		
Session Co-Chairs: TBD		
0830 - 0845	Specific blood/CSF biomarkers/proteomics in FTLD	John van Sweiten Erasmus MC-University, Netherlands
0845 - 0900	Nonspecific blood/CSF biomarkers/proteomics in FTLD	Henrik Zetterberg Univ of Gothenburg, Sweden
0900 - 0915	Electrophysiology	John Caviness Mayo Clinic Arizona, USA
0915 - 0930	Discussion	Session 10 speakers
0930 - 1000	<i>Break</i>	All participants
<b>Session 11: Review of Genetic Findings in FTLD</b>		
Session Co-Chairs: TBD		
1000 - 1015	Key causal genes and pathogenic mechanisms	Caroline Graff Karolinska Institutet, Sweden
1015 - 1030	Rare genes and genetic risk factors	Isabelle Le Ber Sorbonne Univ, France
1030 - 1045	Disease modifying genetic factors	Ekaterina Rogava Univ of Toronto, Canada
1045-1100	Clinical genetic testing in FTLD	Jill Goldman Columbia Univ, USA
<b>Session 12: Update and Controversies – Genetic Issues</b>		
Session Co-Chairs: TBD		
1100 - 1115	Interpreting and disclosing whole exome sequencing/whole genome sequencing findings	Daniel Geschwind UCLA, USA
1115 - 1130	Anticipated discovery - TBD	TBD
1130 - 1145	Anticipated discovery - TBD	TBD
1145 - 1200	Discussion	Session 11 and 12 speakers
1200 - 1300	<i>Lunch</i>	All participants
<b>Session 13: Hot Topics – Imaging, Biomarker and Electrophysiologic Issues</b>		
Session Co-Chairs: TBD		
1300 - 1430	Oral presentations and data blitz	Abstract authors
<b>Session 14: Hot Topics – Genetic Issues</b>		
Session Co-Chairs: TBD		
1430 - 1530	Oral presentations and data blitz	Abstract authors
1530 - 1600	<i>Break</i>	All participants
<b>Session 15: Innovative Measures in FTLD Assessment</b>		
Session Co-Chairs: TBD		
1600 - 1615	Innovative measures for assessing social cognition	Fiona Kumfor Univ of Sydney, Australia
1615 - 1630	Innovative measures for assessing language functioning	Murray Grossman Univ of Pennsylvania, USA
1630 - 1645	Actigraphy/devices/ smartphone apps	Jennifer Merilees UCSF, USA
1645 - 1700	Discussion	Session 15 speakers
<b>Session 16: Hot Topics – Innovative Measures in FTLD Assessment</b>		
Session Co-Chairs: TBD		
1700 - 1730	Oral presentations and data blitz	Abstract authors
<b>Poster Session 2</b>		
1730 - 1900	Poster session – authors stand by posters	All participants
<b>Evening Activities</b>		
1900 - 2200	Dinner (on your own) and social activities TBD	All participants

## Day 3 - Friday, October 9

<b>Time</b>	<b>Event/Title</b>	<b>Speaker/Participants</b>
0645 - 0730	<i>Breakfast</i>	All participants
<b>Session 17: Review of Neuropathologic Findings in FTL D</b>		
Session Co-Chairs: TBD		
0730 - 0745	Tauopathies	Dennis Dickson Mayo Clinic Florida, USA
0745 - 0800	TDPopathies	Eddie Lee Univ of Pennsylvania, USA
0800 - 0815	FUSopathies	Ian Mackenzie Univ of British Columbia, Canada
0815 - 0830	Alzheimer's disease and other pathologies	Irina Alafuzoff Uppsala Univ, Sweden
<b>Session 18: Update and Controversies – Neuropathologic Issues</b>		
Session Co-Chairs: TBD		
0830 - 0845	Late onset FTL D-TDP and LATE	Keith Josephs Mayo Clinic Rochester, USA
0845 - 0900	Copathologies in FTD syndromes	Glenda Halliday Univ of Sydney, Australia
0900 - 0915	Subtyping of molecular pathology	Manuela Neumann Univ of Tübingen, Germany
0915 - 0930	Ultrastructural aspects of proteinopathies	Bernardino Ghetti Indiana Univ, USA
0930 - 0945	Discussion	Session 17 and 18 speakers
0945 - 1015	<i>Break</i>	All participants
<b>Session 19: Review of Molecular Biology/Mechanisms/Models in FTL D</b>		
Session Co-Chairs: TBD		
1015 - 1030	Tau-associated pathophysiology	Michel Goedert Univ of Cambridge, UK
1030 - 1045	TDP-43 associated pathophysiology (unrelated to mutations)	Virginia Lee Univ of Pennsylvania, USA
1045 - 1100	Progranulin-associated pathophysiology	Fenghua Hu Cornell Univ, USA
1100 - 1115	Inflammatory contributions to FTL D pathophysiology	Christian Haass Ludwig-Maximilians-Univ, Germany
<b>Session 20: Update and Controversies – Molecular Biology/Mechanisms/Models in FTL D</b>		
Session Co-Chairs: TBD		
1115 - 1130	C9orf72-associated pathophysiology	Len Petrucelli Mayo Clinic Florida, USA
1130 - 1145	FUS-associated pathophysiology	Sandrine Da Cruz UCSD, USA
1145 - 1200	Model systems	Li Gan Cornell Univ, USA
1200 - 1215	Protein spread	Marc Diamond Univ of Texas Southwestern, USA
1215 - 1230	Discussion	Session 19 and 20 speakers
1230 - 1330	<i>Lunch</i>	All participants
<b>Session 21: Hot Topics – Neuropathologic Issues</b>		
Session Co-Chairs: TBD		
1330 - 1430	Oral presentations and data blitz	Abstract authors
<b>Session 22: Hot Topics – Molecular Biology/Mechanisms/Model Issues</b>		
Session Co-Chairs: TBD		
1430 - 1530	Oral presentations and data blitz	Abstract authors
1530 - 1600	<i>Break</i>	All participants

<b>Session 23: Translational Medicine in FTLD</b>		
Session Co-Chairs: TBD		
1600 - 1615	Antisense oligonucleotide (ASO) therapies	Tim Miller Washington Univ, USA
1615 - 1630	Gene therapies	Erik Roberson Univ of Alabama Birmingham, USA
1630 - 1645	Need for preclinical experiments	Ken Kosik UCSB, USA
1645 - 1700	Bringing new therapies into trials ASAP	Adam Boxer UCSF, USA
<b>Session 24: Piping Hot Topics</b>		
Session Co-Chairs: TBD		
1700 - 1730	Oral presentations and data blitz	Abstract authors
<b>Poster Session 3</b>		
1730 – 1900 (Tentative)	Poster session – authors stand by posters	All participants
<b>Evening Activities</b>		
1900 - 2200	Conference Dinner – US Bank Stadium	Scientific Track Attendees Pre-registration Required

<b>Day 4 - Saturday, October 10 (Optional Day for Family Track Participants)</b>		
<b>Time</b>	<b>Event/Title</b>	<b>Speaker/Participants</b>
0700 - 0800	<i>Breakfast</i>	All participants
<b>Session 25: Review of Drug and Nondrug Strategies for Managing FTLD Symptoms</b>		
Session Co-Chairs: TBD		
0800 - 0815	Management of behavioral aspects of bvFTD	Elizabeth Finger Univ of Western Ontario, Canada
0815 - 0830	Management of aphasia in PPA	Emily Rogalski Northwestern Univ, USA
0830 - 0845	Management of CBD and PSP	Anthony Lang Univ of Toronto, Canada
0845 - 0900	Social and legal issues in FTLD	Mario Mendez UCLA, USA
<b>Session 26: Clinical Trial Issues in FTLD</b>		
Session Co-Chairs: TBD		
0900 - 0915	Recruitment and retention into trials	Mario Masellis Univ of Toronto, Canada
0915 - 0930	Lessons from Alzheimer's disease – the Dominantly Inherited Alzheimer Network (DIAN) Treatment Unit experience	Eric McDade Washington Univ, USA
0930 - 0945	Outcome measures	Adam Staffaroni UCSF, USA
0945 - 1000	Regulatory perspectives	TBD
1000 - 1030	Discussion	Session 25 and 26 speakers
1030 - 1100	<i>Break</i>	All participants
<b>Session 27: Emerging Treatments</b>		
Session Co-Chairs: TBD		
1100 - 1230	Oral presentations	Abstract authors
<b>Conference Closure</b>		
1230 - 1245	Closing comments	ICFTD2020 Organizers
1245 - 1300	ICFTD2022 comments	ICFTD2022 Organizers
1300 -	Ancillary meetings (select participants) and departure	Select participants